Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Controlled, Multicenter, Dose Optimization Study of TTAX03 in the Treatment of Mild to Moderate Dry Eye Disease (DED)

NCT06780306 is registered in ClinicalTrials.gov with BioTissue Holdings, Inc as lead sponsor.

NCT NCT06780306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06780306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Controlled, Multicenter, Dose Optimization Study of TTAX03 in the Treatment of Mild to Moderate Dry Eye Disease (DED)
Lead sponsor
BioTissue Holdings, Inc
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2024
Completion date
January 30, 2026
Enrollment
74 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye, dry eye disease (ded), dry eye disease with severe keratitis